Navigation Links
Alexza Reports 2011 First Quarter Financial Results and Provides Business Update

ements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.", "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations." Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

ALEXZA PHARMACEUTICALS, INC.(a development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)

(unaudited)Three Months EndedMarch 31,20112010Revenue

-Operating expenses:Research and development

6,2627,564General and administrative

2,8205,052Total operating expenses

9,08212,616Income (loss) from operations

(7,823)(12,616)Gain (loss) on change in fair value of contingent consideration liability

-(722)Interest and other income/ (expense), net

10(19)Interest expense

(602)(55)Net income (loss)

(8,415)(13,412)Basic and diluted net loss per share

(0.26)ALEXZA PHARMACEUTICALS, INC.(a development stage company)


(unaudited)March 31, December 31,20112010(1)AssetsCash, cash equivalents and marketable securities


SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza to Present at the MDB Bright Lights Conference 2011
2. Alexza Prices $16.1 Million Registered Direct Offering
3. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
4. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
5. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
6. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
7. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
9. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
10. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
11. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
Post Your Comments:
(Date:5/22/2015)... May 22, 2015  Amgen (NASDAQ: ... commenced termination of its participation in the ... (LON:AZN, STO:AZN and NYSE: AZN ).  ... development for patients with moderate-to-severe plaque psoriasis, ... was based on events of suicidal ideation ...
(Date:5/22/2015)... , May 22, 2015  Effective staffing ... pharmaceutical brand recognition and success. ... a study to provide pharmaceutical and biotech marketing ... (FTEs and budget) that are being channeled into ... biotech marketing managers can utilize this report to ...
(Date:5/22/2015)... TAMPA, Fla. , May 22, 2015 /PRNewswire-USNewswire/ ... Hospital,s Heart Institute recently traveled to ... Convergent procedure at the 2015 Heart Rhythm Society ... experts together to focus on the ideas, people ... Convergent is a hybrid, minimally invasive ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... new and innovative technology has enabled more and more ... office, the central laboratory is hardly threatened with extinction. ... are busier than ever before, and the huge range ... handle very large volumes of tests assures them an ...
... ,Contributing Editor , ,Appendicitis is a common, potentially ... their lives. The condition occurs when the appendix, ... becomes obstructed by mucus, stool, or lymphatic tissue. ... sepsis. The risk of these complications, already elevated ...
Cached Medicine Technology:Immunoassay Systems - Your Laboratory Workhorse 2Appendicitis: Evolving Tools to Diagnose a Classic Disease 2Appendicitis: Evolving Tools to Diagnose a Classic Disease 3
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
(Date:5/22/2015)... DMG Productions announces the upcoming airing of Innovations ... May 29, 2015 at 7:30 a.m. ET and 7:30 ... Innovations will explore Interstate Restoration, a company dedicated to ... recovery and restoration. , Additionally, the series will focus ... and deliver training and education in the areas of ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... May 22, 2015 Puritan Medical ... for the medical, diagnostic, environmental, and forensics industries ... of products in the US. At a time ... outside the US, Puritan remains committed to designing ... their Guilford, Maine facility. , Since 1919, Puritan ...
(Date:5/22/2015)... Viejo, CA (PRWEB) May 22, 2015 ... editable lower thirds designed exclusively for Final Cut Pro ... compatible with any design. , Intuitive on-screen-controls allow ... unique lower third. Reflections, colors, layouts, and much more ... Inspector window. , Pro3rd Impression comes ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... , CUPERTINO, Calif., July 27 ... quarter 2009 financial results press release, you are invited to listen ... internet on Monday, August 3, 2009 at 4:30 pm Eastern Time ... ) , , A live audio webcast ...
... of serious complications drop with intensive therapy, study shows ... controlling blood sugar levels and taking medications that lower ... can significantly reduce their risk of developing the most ... , In a study appearing in the July 27 ...
... 27 Danaher Corporation (NYSE: DHR ) announced today that ... effective as of the end of 2009. , , ... joining Danaher in 2000. , , "Phil ... portfolio over the past nine years," said H. Lawrence Culp, Jr., President ...
... , , ATLANTA, July 27 ... diagnosis and treatment of infertility with ovulation induction and insemination, surgery ... financial aspects. Discussions include information about age related infertility, fallopian tube ... donor eggs. , , You will also ...
... , , , ... Program officials announced today that Tennessee residents have saved over ... launch of the free statewide prescription assistance program. Tennessee Drug ... in May 2007. The program has no restrictions to membership, no ...
... , , MINNEAPOLIS, July 27 ... the world,s population, often resulting in patches of dry skin, and little ... in the teenage years but may continue throughout adulthood. There is ... Alan B. Fleischer, professor and chair of the department of dermatology at ...
Cached Medicine News:Health News:DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2
... SurgiGraphic 1027, with a Carbon Fiber ... designed for superior C-arm access, safety ... design means C-Arm utilization is quick ... exposure is minimized resulting in a ...
... The SurgiGraphic 6000 ... the tabletop for precise ... Float allows for immediate ... moving the C-Arm, making ...
... IMPLANT SYSTEM is a unique three-piece implant ... 1st metatarsal phalangeal joint resulting from osteoarthritis, ... a previous arthroplasty. The implant is ... superior function and longevity. With a ...
... play an important part in our daily ... rheumatic changes can cause severe handicaps. A ... finger-joint prostheses was to produce a reconstructed ... function as nearly possible.,The cementless RM Finger ...
Medicine Products: